Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020115039 - RÉGRESSION DU CANCER PAR INDUCTION D'UNE RÉPONSE DE TYPE RÉGÉNÉRATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. An activator of expression and/or function of YAP and/or TAZ for use in treating or inhibiting cancer, for use in inhibiting progression of tumor growth, or for use in treating or inhibiting tumor metastasis.

2. The activator of expression and/or function of YAP and/or TAZ for use according to claim 1 wherein the activator is directly or indirectly activating function and/or expression of YAP and/or TAZ.

3. The activator of expression and/or function of YAP and/or TAZ for use according to claim 1 or 2 wherein said cancer is liver cancer or said tumor is a liver tumor.

4. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 3, wherein the activator is a pharmacologic compound or a gene therapeutic compound.

5. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 4, wherein the activator of expression and/or function of YAP and/or TAZ is a nucleic acid capable of activating expression and/or function of YAP and/or TAZ, or is a nucleic acid capable of blocking inactivation of expression and/or function of YAP and/or TAZ.

6. The activator of expression and/or function of YAP and/or TAZ for use according to claim 5, wherein the activation of expression and/or function of YAP and/or TAZ is transient or inducible, or wherein the blocking of inactivation of expression and/or function of YAP and/or TAZ is transient or inducible.

7. The activator of expression and/or function of YAP and/or TAZ for use according to claim 5 or 6, wherein the activator is a nucleic acid capable of driving expression of YAP or of a constitutively active YAP variant; a nucleic acid capable of driving expression of TAZ or of a constitutively active TAZ variant; a nucleic acid capable of driving expression of any combination of YAP, TAZ, constitutively active YAP variant, or constitutively active TAZ variant; or any combination of nucleic acids each individually capable of driving expression of YAP, TAZ, constitutively active YAP variant, or constitutively active TAZ variant.

8. The activator of expression and/or function of YAP and/or TAZ for use according to claim 7, wherein the activator is further combined on a same or separate nucleic acid with a gene capable of driving expression of a TEAD transcription factor.

9. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 4, wherein the activator of expression and/or function of YAP and/or TAZ is a glucocorticoid, sphingosine-l-phosphate (SIP), dihydro-SIP, lysophosphatidic acid (LPA), or ethacridine.

10. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 9, wherein the administration is locally to an organ having a cancer or tumor, or is peritumoral, peripheral, or systemic.

11. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 10, wherein the activator is administered in conjunction with macrophage colony-stimulating factor 1 (CSF1), beta-catenin, granulocyte colony-stimulating factor (GCSF), a RAGE-inhibitor, or in conjunction with any combination thereof.

12. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 11, wherein the activator is administered in conjunction with an attenuator of cell division, an antifibrotic agent, or in conjunction with any combination thereof.

13. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 12, wherein the activator is combined in any way with a further anticancer treatment or antitumor agent.

14. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 12 prior to surgical resection of remaining tumor or cancer tissue.

15. The activator of expression and/or function of YAP and/or TAZ for use according to any of claims 1 to 12 prior to administration of an inhibitor of expression and/or function of YAP and/or TAZ.

16. The activator of expression and/or function of YAP and/or TAZ for use according to claim 3 wherein the liver tumor is liver cholangiocarcinoma, hepatocellular carcinoma or a metastatic liver tumor.

17. An activator of liver regeneration for use in treating or inhibiting liver cancer, for use in inhibiting progression of liver tumor growth, or for use in treating or inhibiting liver tumor metastasis.